Stock Analysis on Net
Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

This company has been moved to the archive! The financial data has not been updated since February 15, 2024.

Balance Sheet: Assets
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Vertex Pharmaceuticals Inc., consolidated balance sheet: assets (quarterly data)

US$ in thousands

Microsoft Excel
Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Cash and cash equivalents 10,369,100 11,110,200 10,151,100 9,289,900 10,504,000 9,171,500 8,702,200 7,600,100 6,795,000 6,275,698 6,063,678 6,304,330 5,988,187 5,358,087 4,831,332 3,593,412 3,109,322 3,397,941 3,294,684 2,893,885
Marketable securities 849,200 818,000 1,085,200 1,124,200 274,500 599,200 551,200 638,000 729,900 685,187 644,315 619,638 670,710 792,971 619,437 596,984 698,972 598,390 656,538 584,150
Accounts receivable, net 1,563,400 1,538,700 1,556,200 1,547,800 1,442,200 1,385,200 1,332,900 1,292,800 1,136,800 1,100,372 929,142 977,551 885,352 791,917 791,768 845,269 633,518 443,315 464,900 438,297
Inventories 738,800 688,700 603,500 535,100 460,600 388,200 367,700 338,900 353,100 333,456 321,620 298,863 280,777 245,460 219,218 187,087 167,502 162,306 143,017 136,698
Prepaid expenses and other current assets 623,700 540,200 476,900 468,700 553,500 726,900 549,500 491,500 545,800 457,827 498,759 338,925 308,353 270,021 232,565 223,648 213,515 175,142 151,829 130,009
Current assets 14,144,200 14,695,800 13,872,900 12,965,700 13,234,800 12,271,000 11,503,500 10,361,300 9,560,600 8,852,540 8,457,514 8,539,307 8,133,379 7,458,456 6,694,320 5,446,400 4,822,829 4,777,094 4,710,968 4,183,039
Property and equipment, net 1,159,300 1,124,000 1,122,400 1,111,700 1,108,400 1,118,700 1,100,100 1,107,400 1,094,100 1,042,347 1,021,233 986,123 958,534 920,913 728,357 736,303 745,080 733,509 731,131 742,559
Goodwill 1,088,000 1,088,000 1,088,000 1,088,000 1,088,000 1,075,200 1,002,200 1,002,200 1,002,200 1,002,158 1,002,158 1,002,158 1,002,158 1,002,158 1,002,158 1,002,158 1,002,158 447,525 50,384 50,384
Intangible assets 839,900 603,600 603,600 603,600 603,600 603,600 387,000 400,000 400,000 400,000 400,000 400,000 400,000 400,000 400,000 400,000 400,000 — — —
Deferred tax assets 1,812,100 1,729,100 1,538,000 1,359,900 1,246,900 1,162,700 1,143,800 945,500 934,500 933,839 952,808 815,890 882,779 1,147,816 1,214,968 1,147,705 1,190,815 1,415,511 1,425,191 1,467,518
Operating lease assets 293,600 310,500 324,300 336,300 347,400 342,700 318,300 329,000 330,300 312,343 316,874 322,319 325,564 — — — — — — —
Long-term marketable securities 2,497,800 1,700,000 1,357,300 1,081,500 112,200 — — — — — — — — — — — — — — —
Other assets 895,300 475,200 442,700 427,500 409,600 132,500 127,300 110,700 110,800 75,518 71,099 49,262 49,394 372,290 176,564 160,635 157,583 140,914 115,797 99,614
Long-term assets 8,586,000 7,030,400 6,476,300 6,008,500 4,916,100 4,435,400 4,078,700 3,894,800 3,871,900 3,766,205 3,764,172 3,575,752 3,618,429 3,843,177 3,522,047 3,446,801 3,495,636 2,737,459 2,322,503 2,360,075
Total assets 22,730,200 21,726,200 20,349,200 18,974,200 18,150,900 16,706,400 15,582,200 14,256,100 13,432,500 12,618,745 12,221,686 12,115,059 11,751,808 11,301,633 10,216,367 8,893,201 8,318,465 7,514,553 7,033,471 6,543,114

Based on: 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).

Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Vertex Pharmaceuticals Inc. current assets increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.
Property and equipment, net Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Vertex Pharmaceuticals Inc. property and equipment, net increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Long-term assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Vertex Pharmaceuticals Inc. long-term assets increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Vertex Pharmaceuticals Inc. total assets increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Vertex Pharmaceuticals Inc. cash and cash equivalents increased from Q2 2023 to Q3 2023 but then slightly decreased from Q3 2023 to Q4 2023 not reaching Q2 2023 level.
Marketable securities Amount of investment in marketable security, classified as current. Vertex Pharmaceuticals Inc. marketable securities decreased from Q2 2023 to Q3 2023 but then slightly increased from Q3 2023 to Q4 2023.
Accounts receivable, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Vertex Pharmaceuticals Inc. accounts receivable, net decreased from Q2 2023 to Q3 2023 but then increased from Q3 2023 to Q4 2023 exceeding Q2 2023 level.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Vertex Pharmaceuticals Inc. inventories increased from Q2 2023 to Q3 2023 and from Q3 2023 to Q4 2023.